|
1
|
Bustin M and Reeves R: High-mobility-group
chromosomal proteins: Architectural components that facilitate
chromatin function. Prog Nucleic Acid Res Mol Biol. 54:35–100.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goodwin GH, Sanders C and Johns EW: A new
group of chromatin-associated proteins with a high content of
acidic and basic amino acids. Eur J Biochem. 38:14–19. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bustin M: Revised nomenclature for high
mobility group (HMG) chromosomal proteins. Trends Biochem Sci.
26:152–153. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wood LJ, Maher JF, Bunton TE and Resar LM:
The oncogenic properties of the HMG-I gene family. Cancer Res.
60:4256–4261. 2000.PubMed/NCBI
|
|
5
|
De Martino I, Visone R, Fedele M, Petrocca
F, Palmieri D, Martinez Hoyos J, Forzati F, Croce CM and Fusco A:
Regulation of microRNA expression by HMGA1 proteins. Oncogene.
28:1432–1442. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martinez Hoyos J, Fedele M, Battista S,
Pentimalli F, Kruhoffer M, Arra C, Orntoft TF, Croce CM and Fusco
A: Identification of the genes up- and down-regulated by the high
mobility group A1 (HMGA1) proteins: Tissue specificity of the
HMGA1-dependent gene regulation. Cancer Res. 64:5728–5735. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fedele M, Battista S, Kenyon L,
Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R,
Pierantoni GM, Outwater E, et al: Overexpression of the HMGA2 gene
in transgenic mice leads to the onset of pituitary adenomas.
Oncogene. 21:3190–3198. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huth JR, Bewley CA, Nissen MS, Evans JN,
Reeves R, Gronenborn AM and Clore GM: The solution structure of an
HMG-I(Y)-DNA complex defines a new architectural minor groove
binding motif. Nat Struct Biol. 4:657–665. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thanos D and Maniatis T: The high mobility
group protein HMG I(Y) is required for NF-kappa B-dependent virus
induction of the human IFN-beta gene. Cell. 71:777–789. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tallini G and Dal Cin P: HMGI(Y) and
HMGI-C dysregulation: A common occurrence in human tumors. Adv Anat
Pathol. 6:237–246. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rustighi A, Mantovani F, Fusco A,
Giancotti V and Manfioletti G: Sp1 and CTF/NF-1 transcription
factors are involved in the basal expression of the Hmgi-c proximal
promoter. Biochem Biophys Res Commun. 265:439–447. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ayoubi TA, Jansen E, Meulemans SM and Van
de Ven WJ: Regulation of HMGIC expression: An architectural
transcription factor involved in growth control and development.
Oncogene. 18:5076–5087. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thuault S, Valcourt U, Petersen M,
Manfioletti G, Heldin CH and Moustakas A: Transforming growth
factor-beta employs HMGA2 to elicit epithelial-mesenchymal
transition. J Cell Biol. 174:175–183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wend P, Runke S, Wend K, Anchondo B,
Yesayan M, Jardon M, Hardie N, Loddenkemper C, Ulasov I, Lesniak
MS, et al: WNT10B/β-catenin signalling induces HMGA2 and
proliferation in metastatic triple-negative breast cancer. EMBO Mol
Med. 5:264–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lam K, Muselman A, Du R, Harada Y, Scholl
AG, Yan M, Matsuura S, Weng S, Harada H and Zhang DE: Hmga2 is a
direct target gene of RUNX1 and regulates expansion of myeloid
progenitors in mice. Blood. 124:2203–2212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shell S, Park SM, Radjabi AR, Schickel R,
Kistner EO, Jewell DA, Feig C, Lengyel E and Peter ME: Let-7
expression defines two differentiation stages of cancer. Proc Natl
Acad Sci USA. 104:11400–11405. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee WY, Tzeng CC and Chou CY: Uterine
leiomyosarcomas coexistent with cellular and atypical leiomyomata
in a young woman during the treatment with luteinizing
hormone-releasing hormone agonist. Gynecol Oncol. 52:74–79. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo L, Chen C, Shi M, Wang F, Chen X, Diao
D, Hu M, Yu M, Qian L and Guo N: Stat3-coordinated
Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain
oncostatin M-driven epithelial-mesenchymal transition. Oncogene.
32:5272–5282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Newman MA, Thomson JM and Hammond SM:
Lin-28 interaction with the Let-7 precursor loop mediates regulated
microRNA processing. RNA. 14:1539–1549. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dröge P and Davey CA: Do cells let-7
determine stemness? Cell Stem Cell. 2:8–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Copley MR, Babovic S, Benz C, Knapp DJ,
Beer PA, Kent DG, Wohrer S, Treloar DQ, Day C, Rowe K, et al: The
Lin28b-let-7-Hmga2 axis determines the higher self-renewal
potential of fetal haematopoietic stem cells. Nat Cell Biol.
15:916–925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dangi-Garimella S, Yun J, Eves EM, Newman
M, Erkeland SJ, Hammond SM, Minn AJ and Rosner MR: Raf kinase
inhibitory protein suppresses a metastasis signalling cascade
involving LIN28 and let-7. EMBO J. 28:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun M, Gomes S, Chen P, Frankenberger CA,
Sankarasharma D, Chung CH, Chada KK and Rosner MR: RKIP and HMGA2
regulate breast tumor survival and metastasis through lysyl oxidase
and syndecan-2. Oncogene. 33:3528–3537. 2014. View Article : Google Scholar :
|
|
26
|
Lin Y, Liu AY, Fan C, Zheng H, Li Y, Zhang
C, Wu S, Yu D, Huang Z, Liu F, et al: MicroRNA-33b inhibits breast
cancer metastasis by targeting HMGA2, SALL4 and Twist1. Sci Rep.
5:99952015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim TH, Song JY, Park H, Jeong JY, Kwon
AY, Heo JH, Kang H, Kim G and An HJ: miR-145, targeting
high-mobility group A2, is a powerful predictor of patient outcome
in ovarian carcinoma. Cancer Lett. 356B:937–945. 2015. View Article : Google Scholar
|
|
28
|
Emmrich S, Katsman-Kuipers JE, Henke K,
Khatib ME, Jammal R, Engeland F, Dasci F, Zwaan CM, den Boer ML,
Verboon L, et al: miR-9 is a tumor suppressor in pediatric AML with
t(8;21). Leukemia. 28:1022–1032. 2014. View Article : Google Scholar
|
|
29
|
Liu S, Patel SH, Ginestier C, Ibarra I,
Martin-Trevino R, Bai S, McDermott SP, Shang L, Ke J, Ou SJ, et al:
MicroRNA93 regulates proliferation and differentiation of normal
and malignant breast stem cells. PLoS Genet. 8:e10027512012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye ZH and Gui DW: miR-539 suppresses
proliferation and induces apoptosis in renal cell carcinoma by
targeting high mobility group A2. Mol Med Rep. 17:5611–5618.
2018.PubMed/NCBI
|
|
31
|
Li T, Yang XD, Ye CX, Shen ZL, Yang Y,
Wang B, Guo P, Gao ZD, Ye YJ, Jiang KW, et al: Long noncoding RNA
HIT000218960 promotes papillary thyroid cancer oncogenesis and
tumor progression by upregulating the expression of high mobility
group AT-hook 2 (HMGA2) gene. Cell Cycle. 16:224–231. 2017.
View Article : Google Scholar :
|
|
32
|
Boque-Sastre R, Soler M, Oliveira-Mateos
C, Portela A, Moutinho C, Sayols S, Villanueva A, Esteller M and
Guil S: Head-to-head antisense transcription and R-loop formation
promotes transcriptional activation. Proc Natl Acad Sci USA.
112:5785–5790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou X, Benson KF, Ashar HR and Chada K:
Mutation responsible for the mouse pygmy phenotype in the
developmentally regulated factor HMGI-C. Nature. 376:771–774. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weedon MN, Lettre G, Freathy RM, Lindgren
CM, Voight BF, Perry JR, Elliott KS, Hackett R, Guiducci C, Shields
B, et al Diabetes Genetics Initiative; Wellcome Trust Case Control
Consortium: A common variant of HMGA2 is associated with adult and
childhood height in the general population. Nat Genet.
39:1245–1250. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abi Habib W, Brioude F, Edouard T, Bennett
JT, Lienhardt-Roussie A, Tixier F, Salem J, Yuen T, Azzi S, Le Bouc
Y, et al: Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2
pathway causes fetal growth restriction. Genet Med. 20:250–258.
2018. View Article : Google Scholar
|
|
36
|
Zaidi MR, Okada Y and Chada KK:
Misexpression of full-length HMGA2 induces benign mesenchymal
tumors in mice. Cancer Res. 66:7453–7459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Efanov A, Zanesi N, Coppola V, Nuovo G,
Bolon B, Wernicle-Jameson D, Lagana A, Hansjuerg A, Pichiorri F and
Croce CM: Human HMGA2 protein overexpressed in mice induces
precursor T-cell lymphoblastic leukemia. Blood Cancer J.
4:e2272014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schoenmakers EF, Wanschura S, Mols R,
Bullerdiek J, Van den Berghe H and Van de Ven WJ: Recurrent
rearrangements in the high mobility group protein gene, HMGI-C, in
benign mesenchymal tumours. Nat Genet. 10:436–444. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dreux N, Marty M, Chibon F, Vélasco V,
Hostein I, Ranchère-Vince D, Terrier P and Coindre JM: Value and
limitation of immunohistochemical expression of HMGA2 in
mesenchymal tumors: about a series of 1052 cases. Mod Pathol.
23:1657–1666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marquis M, Beaubois C, Lavallée VP,
Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB,
Fleming S, et al: High expression of HMGA2 independently predicts
poor clinical outcomes in acute myeloid leukemia. Blood Cancer J.
8:682018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang X, Liu X, Li AY, Chen L, Lai L, Lin
HH, Hu S, Yao L, Peng J, Loera S, et al: Overexpression of HMGA2
promotes metastasis and impacts survival of colorectal cancers.
Clin Cancer Res. 17:2570–2580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Malek A, Bakhidze E, Noske A, Sers C,
Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising
target for ovarian cancer silencing therapy. Int J Cancer.
123:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tan L, Wei X, Zheng L, Zeng J, Liu H, Yang
S and Tan H: Amplified HMGA2 promotes cell growth by regulating Akt
pathway in AML. J Cancer Res Clin Oncol. 142:389–399. 2016.
View Article : Google Scholar
|
|
44
|
Tessari MA, Gostissa M, Altamura S, Sgarra
R, Rustighi A, Salvagno C, Caretti G, Imbriano C, Mantovani R, Del
Sal G, et al: Transcriptional activation of the cyclin A gene by
the architectural transcription factor HMGA2. Mol Cell Biol.
23:9104–9116. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Peng L and Seto E: Histone
deacetylase 10 regulates the cell cycle G2/M phase transition via a
novel Let-7-HMGA2-cyclin A2 pathway. Mol Cell Biol. 35:3547–3565.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shaulian E and Karin M: AP-1 as a
regulator of cell life and death. Nat Cell Biol. 4:E131–E136. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vallone D, Battista S, Pierantoni GM,
Fedele M, Casalino L, Santoro M, Viglietto G, Fusco A and Verde P:
Neoplastic transformation of rat thyroid cells requires the junB
and fra-1 gene induction which is dependent on the HMGI-C gene
product. EMBO J. 16:5310–5321. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Evan GI, Brown L, Whyte M and Harrington
E: Apoptosis and the cell cycle. Curr Opin Cell Biol. 7:825–834.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Seville LL, Shah N, Westwell AD and Chan
WC: Modulation of pRB/E2F functions in the regulation of cell cycle
and in cancer. Curr Cancer Drug Targets. 5:159–170. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fedele M, Visone R, De Martino I, Troncone
G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C,
Melillo RM, et al: HMGA2 induces pituitary tumorigenesis by
enhancing E2F1 activity. Cancer Cell. 9:459–471. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu KR, Park SB, Jung JW, Seo MS, Hong IS,
Kim HS, Seo Y, Kang TW, Lee JY, Kurtz A, et al: HMGA2 regulates the
in vitro aging and proliferation of human umbilical cord
blood-derived stromal cells through the mTOR/p70S6K signaling
pathway. Stem Cell Res (Amst). 10:156–165. 2013. View Article : Google Scholar
|
|
52
|
Zhang H, Tang Z, Deng C, He Y, Wu F, Liu O
and Hu C: HMGA2 is associated with the aggressiveness of tongue
squamous cell carcinoma. Oral Dis. 23:255–264. 2017. View Article : Google Scholar
|
|
53
|
Xie H, Wang J, Jiang L, Geng C, Li Q, Mei
D, Zhao L and Cao J: ROS-dependent HMGA2 upregulation mediates
Cd-induced proliferation in MRC-5 cells. Toxicol In Vitro.
34:146–152. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Minshull J, Blow JJ and Hunt T:
Translation of cyclin mRNA is necessary for extracts of activated
Xenopus eggs to enter mitosis. Cell. 56:947–956. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu WD, Tan L, Xiong XF, Liang YP and Tan
H: The effects of lentivirus-mediated RNA interference silencing
HMGA2 on proliferation and expressions of cyclin B2 and cyclin A2
in HL-60 cells. Zhonghua Xue Ye Xue Za Zhi. 33:448–452. 2012.in
Chinese. PubMed/NCBI
|
|
56
|
Branzei D and Foiani M: Maintaining genome
stability at the replication fork. Nat Rev Mol Cell Biol.
11:208–219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Masai H, Tanaka T and Kohda D: Stalled
replication forks: Making ends meet for recognition and
stabilization. BioEssays. 32:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Courcelle J, Donaldson JR, Chow KH and
Courcelle CT: DNA damage-induced replication fork regression and
processing in Escherichia coli. Science. 299:1064–1067. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yu H, Lim HH, Tjokro NO, Sathiyanathan P,
Natarajan S, Chew TW, Klonisch T, Goodman SD, Surana U and Dröge P:
Chaperoning HMGA2 protein protects stalled replication forks in
stem and cancer cells. Cell Rep. 6:684–697. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Iyama T and Wilson DM III: DNA repair
mechanisms in dividing and non-dividing cells. DNA Repair (Amst).
12:620–636. 2013. View Article : Google Scholar
|
|
61
|
Bartkova J, Rajpert-De Meyts E, Skakkebaek
NE, Lukas J and Bartek J: DNA damage response in human testes and
testicular germ cell tumours: Biology and implications for therapy.
Int J Androl. 30:282–291; discussion 291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shrivastav M, De Haro LP and Nickoloff JA:
Regulation of DNA double-strand break repair pathway choice. Cell
Res. 18:134–147. 2008. View Article : Google Scholar
|
|
63
|
Lieber MR: The mechanism of double-strand
DNA break repair by the nonhomologous DNA end-joining pathway. Annu
Rev Biochem. 79:181–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Arnoult N, Correia A, Ma J, Merlo A,
Garcia-Gomez S, Maric M, Tognetti M, Benner CW, Boulton SJ,
Saghatelian A, et al: Regulation of DNA repair pathway choice in S
and G2 phases by the NHEJ inhibitor CYREN. Nature. 549:548–552.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Meek K, Dang V and Lees-Miller SP: DNA-PK:
The means to justify the ends? Adv Immunol. 99:33–58. 2008.
View Article : Google Scholar
|
|
66
|
Uematsu N, Weterings E, Yano K,
Morotomi-Yano K, Jakob B, Taucher-Scholz G, Mari PO, van Gent DC,
Chen BP and Chen DJ: Autophosphorylation of DNA-PKCS regulates its
dynamics at DNA double-strand breaks. J Cell Biol. 177:219–229.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Downs JA, Lowndes NF and Jackson SP: A
role for Saccharomyces cerevisiae histone H2A in DNA repair.
Nature. 408:1001–1004. 2000. View Article : Google Scholar
|
|
68
|
Nick McElhinny SA, Snowden CM, McCarville
J and Ramsden DA: Ku recruits the XRCC4-ligase IV complex to DNA
ends. Mol Cell Biol. 20:2996–3003. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li AY, Boo LM, Wang SY, Lin HH, Wang CC,
Yen Y, Chen BP, Chen DJ and Ann DK: Suppression of nonhomologous
end joining repair by overexpression of HMGA2. Cancer Res.
69:5699–5706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kühne C, Tjörnhammar ML, Pongor S, Banks L
and Simoncsits A: Repair of a minimal DNA double-strand break by
NHEJ requires DNA-PKcs and is controlled by the ATM/ATR checkpoint.
Nucleic Acids Res. 31:7227–7237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bullerdiek J and Rommel B: Comment re:
HMGA2 is a negative regulator of DNA-PK pathway. Cancer Res.
70:1742author reply 1742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cleynen I and Van de Ven WJ: The HMGA
proteins: A myriad of functions (Review). Int J Oncol. 32:289–305.
2008.PubMed/NCBI
|
|
73
|
Boo LM, Lin HH, Chung V, Zhou B, Louie SG,
O'Reilly MA, Yen Y and Ann DK: High mobility group A2 potentiates
genotoxic stress in part through the modulation of basal and DNA
damage-dependent phosphatidylinositol 3-kinase-related protein
kinase activation. Cancer Res. 65:6622–6630. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Palmieri D, Valentino T, D'Angelo D, De
Martino I, Postiglione I, Pacelli R, Croce CM, Fedele M and Fusco
A: HMGA proteins promote ATM expression and enhance cancer cell
resistance to genotoxic agents. Oncogene. 30:3024–3035. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Natarajan S, Hombach-Klonisch S, Dröge P
and Klonisch T: HMGA2 inhibits apoptosis through interaction with
ATR-CHK1 signaling complex in human cancer cells. Neoplasia.
15:263–280. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jackson SP and Bartek J: The DNA-damage
response in human biology and disease. Nature. 461:1071–1078. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Summer H, Li O, Bao Q, Zhan L, Peter S,
Sathiyanathan P, Henderson D, Klonisch T, Goodman SD and Dröge P:
HMGA2 exhibits dRP/AP site cleavage activity and protects cancer
cells from DNA-damage-induced cytotoxicity during chemotherapy.
Nucleic Acids Res. 37:4371–4384. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hombach-Klonisch S, Kalantari F, Medapati
MR, Natarajan S, Krishnan SN, Kumar-Kanojia A, Thanasupawat T,
Begum F, Xu FY, Hatch GM, et al: HMGA2 as a functional antagonist
of PARP1 inhibitors in tumor cells. Mol Oncol. 13:153–170. 2019.
View Article : Google Scholar :
|
|
79
|
Alekseev S and Coin F: Orchestral
maneuvers at the damaged sites in nucleotide excision repair. Cell
Mol Life Sci. 72:2177–2186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
de Laat WL, Jaspers NG and Hoeijmakers JH:
Molecular mechanism of nucleotide excision repair. Genes Dev.
13:768–785. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Westerveld A, Hoeijmakers JH, van Duin M,
de Wit J, Odijk H, Pastink A, Wood RD and Bootsma D: Molecular
cloning of a human DNA repair gene. Nature. 310:425–429. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Borrmann L, Schwanbeck R, Heyduk T,
Seebeck B, Rogalla P, Bullerdiek J and Wisniewski JR: High mobility
group A2 protein and its derivatives bind a specific region of the
promoter of DNA repair gene ERCC1 and modulate its activity.
Nucleic Acids Res. 31:6841–6851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Cotter TG: Apoptosis and cancer: The
genesis of a research field. Nat Rev Cancer. 9:501–507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Taylor RC, Cullen SP and Martin SJ:
Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol
Cell Biol. 9:231–241. 2008. View Article : Google Scholar
|
|
85
|
Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan
Z and Ai K: H19 promotes pancreatic cancer metastasis by
derepressing let-7's suppression on its target HMGA2-mediated EMT.
Tumour Biol. 35:9163–9169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Jia J, Yang M, Chen Y, Yuan H, Li J, Cui X
and Liu Z: Inducing apoptosis effect of caffeic acid
3,4-dihydroxy-phenethyl ester on the breast cancer cells. Tumour
Biol. 35:11781–11789. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Sionov RV and Haupt Y: The cellular
response to p53: The decision between life and death. Oncogene.
18:6145–6157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Meier P and Vousden KH: Lucifer's
labyrinth - ten years of path finding in cell death. Mol Cell.
28:746–754. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pentimalli F, Dentice M, Fedele M,
Pierantoni GM, Cito L, Pallante P, Santoro M, Viglietto G, Dal Cin
P and Fusco A: Suppression of HMGA2 protein synthesis could be a
tool for the therapy of well differentiated liposarcomas
overexpressing HMGA2. Cancer Res. 63:7423–7427. 2003.PubMed/NCBI
|
|
90
|
Kaur H, Hütt-Cabezas M, Weingart MF, Xu J,
Kuwahara Y, Erdreich-Epstein A, Weissman BE, Eberhart CG and Raabe
EH: The chromatin-modifying protein HMGA2 promotes atypical
teratoid/rhabdoid cell tumorigenicity. J Neuropathol Exp Neurol.
74:177–185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Mansoori B, Mohammadi A, Shirjang S and
Baradaran B: HMGI-C suppressing induces P53/caspase-9 axis to
regulate apoptosis in breast adenocarcinoma cells. Cell Cycle.
15:2585–2592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Gao X, Dai M, Li Q, Wang Z, Lu Y and Song
Z: HMGA2 regulates lung cancer proliferation and metastasis. Thorac
Cancer. 8:Jul 28–2017.Epub ahead of print. View Article : Google Scholar
|
|
93
|
Basolo F, Fiore L, Fusco A, Giannini R,
Albini A, Merlo GR, Fontanini G, Conaldi PG and Toniolo A:
Potentiation of the malignant phenotype of the undifferentiated ARO
thyroid cell line by insertion of the bcl-2 gene. Int J Cancer.
81:956–962. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Sos ML, Fischer S, Ullrich R, Peifer M,
Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F,
et al: Identifying genotype-dependent efficacy of single and
combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl
Acad Sci USA. 106:18351–18356. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang XT, Pei DS, Xu J, Guan QH, Sun YF,
Liu XM and Zhang GY: Opposing effects of Bad phosphorylation at two
distinct sites by Akt1 and JNK1/2 on ischemic brain injury. Cell
Signal. 19:1844–1856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wei CH, Wei LX, Lai MY, Chen JZ and Mo XJ:
Effect of silencing of high mobility group A2 gene on gastric
cancer MKN-45 cells. World J Gastroenterol. 19:1239–1246. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Shi X, Tian B, Ma W, Zhang N, Qiao Y, Li
X, Zhang Y, Huang B and Lu J: A novel anti-proliferative role of
HMGA2 in induction of apoptosis through caspase 2 in primary human
fibroblast cells. Biosci Rep. 35:e001692015. View Article : Google Scholar
|
|
100
|
Fujikane R, Komori K, Sekiguchi M and
Hidaka M: Function of high-mobility group A proteins in the DNA
damage signaling for the induction of apoptosis. Sci Rep.
6:317142016. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang WY, Cao YX, Zhou X, Wei B, Zhan L and
Fu LT: HMGA2 gene silencing reduces epithelial-mesenchymal
transition and lymph node metastasis in cervical cancer through
inhibiting the ATR/Chk1 signaling pathway. Am J Transl Res.
10:3036–3052. 2018.PubMed/NCBI
|
|
102
|
Haselmann V, Kurz A, Bertsch U, Hübner S,
Olempska-Müller M, Fritsch J, Häsler R, Pickl A, Fritsche H,
Annewanter F, et al: Nuclear death receptor TRAIL-R2 inhibits
maturation of let-7 and promotes proliferation of pancreatic and
other tumor cells. Gastroenterology. 146:278–290. 2014. View Article : Google Scholar
|
|
103
|
Hayflick L: The limited in vitro lifetime
of human diploid cell strains. Exp Cell Res. 37:614–636. 1965.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
d'Adda di Fagagna F: Living on a break:
Cellular senescence as a DNA-damage response. Nat Rev Cancer.
8:512–522. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Matsumura T, Zerrudo Z and Hayflick L:
Senescent human diploid cells in culture: Survival, DNA synthesis
and morphology. J Gerontol. 34:328–334. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Muñoz-Espín D, Cañamero M, Maraver A,
Gómez-López G, Contreras J, Murillo-Cuesta S, Rodríguez-Baeza A,
Varela-Nieto I, Ruberte J, Collado M, et al: Programmed cell
senescence during mammalian embryonic development. Cell.
155:1104–1118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Storer M, Mas A, Robert-Moreno A, Pecoraro
M, Ortells MC, Di Giacomo V, Yosef R, Pilpel N, Krizhanovsky V,
Sharpe J, et al: Senescence is a developmental mechanism that
contributes to embryonic growth and patterning. Cell.
155:1119–1130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Artandi SE and DePinho RA: A critical role
for telomeres in suppressing and facilitating carcinogenesis. Curr
Opin Genet Dev. 10:39–46. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Michaloglou C, Vredeveld LC, Soengas MS,
Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi
WJ and Peeper DS: BRAFE600-associated senescence-like cell cycle
arrest of human naevi. Nature. 436:720–724. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Chen Z, Trotman LC, Shaffer D, Lin HK,
Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al:
Crucial role of p53-dependent cellular senescence in suppression of
Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Bringold F and Serrano M: Tumor
suppressors and oncogenes in cellular senescence. Exp Gerontol.
35:317–329. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Dimri GP, Itahana K, Acosta M and Campisi
J: Regulation of a senescence checkpoint response by the E2F1
transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol.
20:273–285. 2000. View Article : Google Scholar
|
|
113
|
Sharpless NE: INK4a/ARF: A multifunctional
tumor suppressor locus. Mutat Res. 576:22–38. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kim WY and Sharpless NE: The regulation of
INK4/ARF in cancer and aging. Cell. 127:265–275. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Krishnamurthy J, Torrice C, Ramsey MR,
Kovalev GI, Al-Regaiey K, Su L and Sharpless NE: Ink4a/Arf
expression is a biomarker of aging. J Clin Invest. 114:1299–1307.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Collado M and Serrano M: The power and the
promise of oncogene-induced senescence markers. Nat Rev Cancer.
6:472–476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Markowski DN, Bartnitzke S, Belge G,
Drieschner N, Helmke BM and Bullerdiek J: Cell culture and
senescence in uterine fibroids. Cancer Genet Cytogenet. 202:53–57.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Nishino J, Kim I, Chada K and Morrison SJ:
Hmga2 promotes neural stem cell self-renewal in young but not old
mice by reducing p16Ink4a and p19Arf
expression. Cell. 135:227–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Markowski DN, Winter N, Meyer F, von Ahsen
I, Wenk H, Nolte I and Bullerdiek J: p14Arf acts as an
antagonist of HMGA2 in senescence of mesenchymal stem
cells-implications for benign tumorigenesis. Genes Chromosomes
Cancer. 50:489–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhu S, Deng S, Ma Q, Zhang T, Jia C, Zhuo
D, Yang F, Wei J, Wang L, Dykxhoorn DM, et al:
MicroRNA-10A* and microRNA-21 modulate endothelial
progenitor cell senescence via suppressing high-mobility group A2.
Circ Res. 112:152–164. 2013. View Article : Google Scholar
|
|
121
|
Federico A, Forzati F, Esposito F, Arra C,
Palma G, Barbieri A, Palmieri D, Fedele M, Pierantoni GM, De
Martino I, et al: Hmga1/Hmga2 double knock-out mice display a
'superpygmy' phenotype. Biol Open. 3:372–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Shi X, Tian B, Liu L, Gao Y, Ma C, Mwichie
N, Ma W, Han L, Huang B, Lu J, et al: Rb protein is essential to
the senescence-associated heterochromatic foci formation induced by
HMGA2 in primary WI38 cells. J Genet Genomics. 40:391–398. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Narita M, Narita M, Krizhanovsky V, Nuñez
S, Chicas A, Hearn SA, Myers MP and Lowe SW: A novel role for
high-mobility group a proteins in cellular senescence and
heterochromatin formation. Cell. 126:503–514. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Yentrapalli R, Azimzadeh O, Sriharshan A,
Malinowsky K, Merl J, Wojcik A, Harms-Ringdahl M, Atkinson MJ,
Becker KF, Haghdoost S, et al: The PI3K/Akt/mTOR pathway is
implicated in the premature senescence of primary human endothelial
cells exposed to chronic radiation. PLoS One. 8:e700242013.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kennedy AL, Morton JP, Manoharan I, Nelson
DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien
KA, et al: Activation of the PIK3CA/AKT pathway suppresses
senescence induced by an activated RAS oncogene to promote
tumorigenesis. Mol Cell. 42:36–49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Courtois-Cox S, Genther Williams SM,
Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein
PE, MacCollin M and Cichowski K: A negative feedback signaling
network underlies oncogene-induced senescence. Cancer Cell.
10:459–472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Xu X, Lu Z, Qiang W, Vidimar V, Kong B,
Kim JJ and Wei JJ: Inactivation of AKT induces cellular senescence
in uterine leiomyoma. Endocrinology. 155:1510–1519. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesen-chymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: Implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial- mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kirschmann DA, Seftor EA, Nieva DR,
Mariano EA and Hendrix MJ: Differentially expressed genes
associated with the metastatic phenotype in breast cancer. Breast
Cancer Res Treat. 55:127–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Wu J, Zhang S, Shan J, Hu Z, Liu X, Chen
L, Ren X, Yao L, Sheng H, Li L, et al: Elevated HMGA2 expression is
associated with cancer aggressiveness and predicts poor outcome in
breast cancer. Cancer Lett. 376:284–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Liu Q, Liu T, Zheng S, Gao X, Lu M,
Sheyhidin I and Lu X: HMGA2 is down-regulated by microRNA let-7 and
associated with epithelial-mesenchymal transition in oesophageal
squamous cell carcinomas of Kazakhs. Histopathology. 65:408–417.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Watanabe S, Ueda Y, Akaboshi S, Hino Y,
Sekita Y and Nakao M: HMGA2 maintains oncogenic RAS-induced
epithelial-mesenchymal transition in human pancreatic cancer cells.
Am J Pathol. 174:854–868. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Thuault S, Tan EJ, Peinado H, Cano A,
Heldin CH and Moustakas A: HMGA2 and Smads co-regulate SNAIL1
expression during induction of epithelial-to-mesenchymal
transition. J Biol Chem. 283:33437–33446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Morishita A, Zaidi MR, Mitoro A,
Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K:
HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Liu H, Wang X, Liu S and Li H, Yuan X,
Feng B, Bai H, Zhao B, Chu Y and Li H: Effects and mechanism of
miR-23b on glucose-mediated epithelial-to-mesenchymal transition in
diabetic nephropathy. Int J Biochem Cell Biol. 70:149–160. 2016.
View Article : Google Scholar
|
|
139
|
Zha L, Zhang J, Tang W, Zhang N, He M, Guo
Y and Wang Z: HMGA2 elicits EMT by activating the Wnt/β-catenin
pathway in gastric cancer. Dig Dis Sci. 58:724–733. 2013.
View Article : Google Scholar
|
|
140
|
Sakai D, Suzuki T, Osumi N and Wakamatsu
Y: Cooperative action of Sox9, Snail2 and PKA signaling in early
neural crest development. Development. 133:1323–1333. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Tan EJ, Kahata K, Idås O, Thuault S,
Heldin CH and Moustakas A: The high mobility group A2 protein
epigenetically silences the Cdh1 gene during
epithelial-to-mesenchymal transition. Nucleic Acids Res.
43:162–178. 2015. View Article : Google Scholar :
|
|
142
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Singh I, Mehta A, Contreras A, Boettger T,
Carraro G, Wheeler M, Cabrera-Fuentes HA, Bellusci S, Seeger W,
Braun T, et al: Hmga2 is required for canonical WNT signaling
during lung development. BMC Biol. 12:212014. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Queimado L, Lopes CS and Reis AM: WIF1, an
inhibitor of the Wnt pathway, is rearranged in salivary gland
tumors. Genes Chromosomes Cancer. 46:215–225. 2007. View Article : Google Scholar
|
|
145
|
Dong J, Wang R, Ren G, Li X, Wang J, Sun
Y, Liang J, Nie Y, Wu K, Feng B, et al: HMGA2-FOXL2 Axis regulates
metastases and epithelial-to-mesenchymal transition of
chemoresistant gastric cancer. Clin Cancer Res. 23:3461–3473. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Bodnar AG: Marine invertebrates as models
for aging research. Exp Gerontol. 44:477–484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
d'Adda di Fagagna F, Reaper PM,
Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G,
Carter NP and Jackson SP: A DNA damage checkpoint response in
telomere-initiated senescence. Nature. 426:194–198. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Harley CB: Telomerase and cancer
therapeutics. Nat Rev Cancer. 8:167–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Li AY, Lin HH, Kuo CY, Shih HM, Wang CC,
Yen Y and Ann DK: High-mobility group A2 protein modulates hTERT
transcription to promote tumorigenesis. Mol Cell Biol.
31:2605–2617. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Natarajan S, Begum F, Gim J, Wark L,
Henderson D, Davie JR, Hombach-Klonisch S and Klonisch T: High
mobility group A2 protects cancer cells against telomere
dysfunction. Oncotarget. 7:12761–12782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Qian YW, Gao JH, Lu F and Zheng XD: The
differences between adipose tissue derived stem cells and lipoma
mesen-chymal stem cells in characteristics. Zhonghua Zheng Xing Wai
Ke Za Zhi. 26:125–132. 2010.In Chinese. PubMed/NCBI
|
|
152
|
Okamoto K, Bartocci C, Ouzounov I,
Diedrich JK, Yates JR III and Denchi EL: A two-step mechanism for
TRF2-mediated chromosome-end protection. Nature. 494:502–505. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Fojo T: Cancer, DNA repair mechanisms, and
resistance to chemotherapy. J Natl Cancer Inst. 93:1434–1436. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Schmitt CA, Fridman JS, Yang M, Lee S,
Baranov E, Hoffman RM and Lowe SW: A senescence program controlled
by p53 and p16INK4a contributes to the outcome of cancer
therapy. Cell. 109:335–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Marijon H, Dokmak S, Paradis V, Zappa M,
Bieche I, Bouattour M, Raymond E and Faivre S:
Epithelial-to-mesenchymal transition and acquired resistance to
sunitinib in a patient with hepato-cellular carcinoma. J Hepatol.
54:1073–1078. 2011. View Article : Google Scholar
|
|
156
|
Dangi-Garimella S, Krantz SB, Barron MR,
Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ and Munshi HG:
Three-dimensional collagen I promotes gemcitabine resistance in
pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Cancer Res. 71:1019–1028. 2011. View Article : Google Scholar
|
|
157
|
Dangi-Garimella S, Sahai V, Ebine K, Kumar
K and Munshi HG: Three-dimensional collagen I promotes gemcitabine
resistance in vitro in pancreatic cancer cells through
HMGA2-dependent histone acetyltransferase expression. PLoS One.
8:e645662013. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Giannini G, Di Marcotullio L, Ristori E,
Zani M, Crescenzi M, Scarpa S, Piaggio G, Vacca A, Peverali FA,
Diana F, et al: HMGI(Y) and HMGI-C genes are expressed in
neuroblastoma cell lines and tumors and affect retinoic acid
responsiveness. Cancer Res. 59:2484–2492. 1999.PubMed/NCBI
|
|
159
|
Xia YY, Yin L, Tian H, Guo WJ, Jiang N,
Jiang XS, Wu J, Chen M, Wu JZ and He X: HMGA2 is associated with
epithelial-mesenchymal transition and can predict poor prognosis in
nasopharyngeal carcinoma. OncoTargets Ther. 8:169–176. 2015.
View Article : Google Scholar
|
|
160
|
Davidson B, Holth A, Hellesylt E, Tan TZ,
Huang RY, Tropé C, Nesland JM and Thiery JP: The clinical role of
epithelial-mesen-chymal transition and stem cell markers in
advanced-stage ovarian serous carcinoma effusions. Hum Pathol.
46:1–8. 2015. View Article : Google Scholar
|
|
161
|
Rogalla P, Drechsler K, Kazmierczak B,
Rippe V, Bonk U and Bullerdiek J: Expression of HMGI-C, a member of
the high mobility group protein family, in a subset of breast
cancers: Relationship to histologic grade. Mol Carcinog.
19:153–156. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Lee CT, Wu TT, Lohse CM and Zhang L:
High-mobility group AT-hook 2: An independent marker of poor
prognosis in intrahepatic cholangiocarcinoma. Hum Pathol.
45:2334–2340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Hristov AC, Cope L, Reyes MD, Singh M,
Iacobuzio-Donahue C, Maitra A and Resar LM: HMGA2 protein
expression correlates with lymph node metastasis and increased
tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol.
22:43–49. 2009. View Article : Google Scholar :
|
|
164
|
Yang GL, Zhang LH, Bo JJ, Hou KL, Cai X,
Chen YY, Li H, Liu DM and Huang YR: Overexpression of HMGA2 in
bladder cancer and its association with clinicopathologic features
and prognosis HMGA2 as a prognostic marker of bladder cancer. Eur J
Surg Oncol. 37:265–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zou Q, Xiong L, Yang Z, Lv F, Yang L and
Miao X: Expression levels of HMGA2 and CD9 and its
clinicopathological signifi-cances in the benign and malignant
lesions of the gallbladder. World J Surg Oncol. 10:922012.
View Article : Google Scholar
|
|
166
|
Lee CT, Zhang L, Mounajjed T and Wu TT:
High mobility group AT-hook 2 is overexpressed in hepatoblastoma.
Hum Pathol. 44:802–810. 2013. View Article : Google Scholar
|
|
167
|
Raskin L, Fullen DR, Giordano TJ, Thomas
DG, Frohm ML, Cha KB, Ahn J, Mukherjee B, Johnson TM and Gruber SB:
Transcriptome profiling identifies HMGA2 as a biomarker of melanoma
progression and prognosis. J Invest Dermatol. 133:2585–2592. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Qian ZR, Asa SL, Siomi H, Siomi MC,
Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, Itakura M, et
al: Overexpression of HMGA2 relates to reduction of the let-7 and
its relationship to clinicopathological features in pituitary
adenomas. Mod Pathol. 22:431–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Belge G, Meyer A, Klemke M, Burchardt K,
Stern C, Wosniok W, Loeschke S and Bullerdiek J: Upregulation of
HMGA2 in thyroid carcinomas: A novel molecular marker to
distinguish between benign and malignant follicular neoplasias.
Genes Chromosomes Cancer. 47:56–63. 2008. View Article : Google Scholar
|
|
170
|
Zhang S, Zhang H and Yu L: HMGA2 promotes
glioma invasion and poor prognosis via a long-range chromatin
interaction. Cancer Med. 7:3226–3239. 2018. View Article : Google Scholar :
|
|
171
|
Na N, Si T, Huang Z, Miao B, Hong L, Li H
and Qiu J and Qiu J: High expression of HMGA2 predicts poor
survival in patients with clear cell renal cell carcinoma.
OncoTargets Ther. 9:7199–7205. 2016. View Article : Google Scholar
|
|
172
|
Günther K, Foraita R, Friemel J, Günther
F, Bullerdiek J, Nimzyk R, Markowski DN, Behrens T and Ahrens W:
The stem cell factor HMGA2 is expressed in non-HPV-associated head
and neck squamous cell carcinoma and predicts patient survival of
distinct subsites. Cancer Epidemiol Biomarkers Prev. 26:197–205.
2017. View Article : Google Scholar
|
|
173
|
Mito JK, Agoston AT, Dal Cin P and
Srivastava A: Prevalence and significance of HMGA2 expression in
oesophageal adeno-carcinoma. Histopathology. 71:909–917. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Sarhadi VK, Wikman H, Salmenkivi K, Kuosma
E, Sioris T, Salo J, Karjalainen A, Knuutila S and Anttila S:
Increased expression of high mobility group A proteins in lung
cancer. J Pathol. 209:206–212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Di Cello F, Hillion J, Hristov A, Wood LJ,
Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R
and Resar LM: HMGA2 participates in transformation in human lung
cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Strell C, Norberg KJ, Mezheyeuski A,
Schnittert J, Kuninty PR, Moro CF, Paulsson J, Schultz NA,
Calatayud D, Löhr JM, et al: Stroma-regulated HMGA2 is an
independent prognostic marker in PDAC and AAC. Br J Cancer.
117:65–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Motoyama K, Inoue H, Nakamura Y, Uetake H,
Sugihara K and Mori M: Clinical significance of high mobility group
A2 in human gastric cancer and its relationship to let-7 microRNA
family. Clin Cancer Res. 14:2334–2340. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Berlingieri MT, Manfioletti G, Santoro M,
Bandiera A, Visconti R, Giancotti V and Fusco A: Inhibition of
HMGI-C protein synthesis suppresses retrovirally induced neoplastic
transformation of rat thyroid cells. Mol Cell Biol. 15:1545–1553.
1995. View Article : Google Scholar : PubMed/NCBI
|
